Specifically, after inhibiting FSP1, there was a significant decrease in CoQ10H2 (Figures 6B, 7B), an increase in MDA (Figures 6C, 7D), an increase in Fe2+ (Figures 6D, 7E), a greater reduction in mitochondrial membrane potential (Figure 6F), decreased cell viability, and elevated NT-proBNP (Figures 6E, 7J), increased myocardial hypertrophy (Figures 7F, G), reduced LVEF (Figures 7H, I), increased myocardial fibrosis (Figures 7K, L), and aggravated mitochondrial shrinkage and cristae fusion (Figure 7C). The gene discussed is AIFM2; the disease is Myocardial fibrosis.